Cell surface expression of glycosylated, nonglycosylated, and truncated forms of a cytoplasmic protein pyruvate kinase. Hiebert SW, Lamb RA (1988) J Cell Biol 107: 865-76 Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. Barbas CF, Crowe JE, Cababa D, Jones TM, Zebedee SL, Murphy BR, Chanock RM, Burton DR (1992) Proc Natl Acad Sci U S A 89: 10164-8 Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus. Fisher RG, Crowe JE, Johnson TR, Tang YW, Graham BS (1999) J Infect Dis 180: 1324-7 Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo. Crowe JE, Gilmour PS, Murphy BR, Chanock RM, Duan L, Pomerantz RJ, Pilkington GR (1998) J Infect Dis 177: 1073-6 Different roles of individual N-linked oligosaccharide chains in folding, assembly, and transport of the simian virus 5 hemagglutinin-neuraminidase. Ng DT, Hiebert SW, Lamb RA (1990) Mol Cell Biol 10: 1989-2001 The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein. Juhasz K, Whitehead SS, Bui PT, Biggs JM, Crowe JE, Boulanger CA, Collins PL, Murphy BR (1997) J Virol 71: 5814-9 Loss of the N-linked glycan at residue 173 of human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site. Alymova IV, Taylor G, Mishin VP, Watanabe M, Murti KG, Boyd K, Chand P, Babu YS, Portner A (2008) J Virol 82: 8400-10 Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus. Kulkarni AB, Collins PL, Bacik I, Yewdell JW, Bennink JR, Crowe JE, Murphy BR (1995) J Virol 69: 1261-4 Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. Whitehead SS, Firestone CY, Karron RA, Crowe JE, Elkins WR, Collins PL, Murphy BR (1999) J Virol 73: 871-7 RhoA interacts with the fusion glycoprotein of respiratory syncytial virus and facilitates virus-induced syncytium formation. Pastey MK, Crowe JE, Graham BS (1999) J Virol 73: 7262-70 The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae. Alymova IV, Portner A, Takimoto T, Boyd KL, Babu YS, McCullers JA (2005) Antimicrob Agents Chemother 49: 398-405 A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Crowe JE, Collins PL, London WT, Chanock RM, Murphy BR (1993) Vaccine 11: 1395-404 A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes. Connors M, Crowe JE, Firestone CY, Murphy BR, Collins PL (1995) Virology 208: 478-84 Efficacy of the novel parainfluenza virus haemagglutinin-neuraminidase inhibitor BCX 2798 in mice - further evaluation. Alymova IV, Watanabe M, Boyd KL, Chand P, Babu YS, Portner A (2009) Antivir Ther 14: 891-8
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.